Breaking News, Collaborations & Alliances

Haisco Grants AbbVie Exclusive Rights to Advance Novel Pain Medicines

The program includes multiple compounds designed to address pain-related indications.

Author Image

By: Charlie Sternberg

Associate Editor

Haisco Pharmaceutical Group Co. Ltd. has entered into an exclusive licensing agreement with AbbVie, under which Haisco grants AbbVie the exclusive rights to develop, manufacture, and commercialize novel medicines for the treatment of pain globally, excluding mainland China, Hong Kong, and Macau. The collaboration strengthens Haisco’s global presence and pipeline by leveraging AbbVie’s development and commercialization capabilities, as well as its expertise in neuroscience. Hais...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters